Insider Trading Summary for Allogene Therapeutics, Inc. (ALLO): Year

Recent Insider Trades

Last Transaction		Last Three Months
SEC Filing	Transaction	Insider	Sentiment	Company	Holdings Change	Buy Amount	Sell Amount	Buy Price Range	Sell Price Range
18-Mar-24 8:10 PM View:	14-Mar-24 Payment of Exercise ($231.19K)	Chang David D President and CEO Director		Allogene Therapeutics, Inc. - ALLO	4% 7.11M to 7.38M	0	0	--	--	Show Txns Hide Txns

15-Jun-23 5:01 PM View:	13-Jun-23 Grant 0	Humer Franz B Director		Allogene Therapeutics, Inc. - ALLO	39% 191.89K to 266.45K	0	0	--	--	Show Txns Hide Txns

15-Jun-23 5:00 PM View:	13-Jun-23 Grant 0	Witte Owen N. Director		Allogene Therapeutics, Inc. - ALLO	34% 218.27K to 292.83K	0	0	--	--	Show Txns Hide Txns

20-Dec-23 4:26 PM View:	18-Dec-23 Sale (Planned) ($50.32K)	Messemer Deborah M. Director		Allogene Therapeutics, Inc. - ALLO	856% 6.54K to 62.46K	0	0	--	--	Show Txns Hide Txns

31-Jan-24 5:46 PM View:	25-Jan-24 Grant 0	Belldegrun Arie Director		Allogene Therapeutics, Inc. - ALLO	3% 8.36M to 8.57M	0	0	--	--	Show Txns Hide Txns

15-Jun-23 5:02 PM View:	13-Jun-23 Grant 0	Sato Vicki L Director		Allogene Therapeutics, Inc. - ALLO	144% 41.45K to 101.1K	0	0	--	--	Show Txns Hide Txns

09-Aug-23 4:07 PM View:	07-Aug-23 Sale ($42.86K)	Mayo Stephen Director		Allogene Therapeutics, Inc. - ALLO	(28%) 35.33K to 25.33K	0	0	--	--	Show Txns Hide Txns

31-Jan-24 5:45 PM View:	25-Jan-24 Grant 0	Roberts Zachary EVP of R&D		Allogene Therapeutics, Inc. - ALLO	29% 399.94K to 515.25K	0	0	--	--	Show Txns Hide Txns

24-Apr-24 4:18 PM View:	22-Apr-24 Payment of Exercise ($60.19K)	Moore Timothy L. Chief Technical Officer		Allogene Therapeutics, Inc. - ALLO	43% 186.22K to 265.46K	0	0	--	--	Show Txns Hide Txns

14-Aug-23 7:59 PM View:	10-Aug-23 Grant 0	Chen Yinlin Jack SVP, Finance		Allogene Therapeutics, Inc. - ALLO	15% 77.48K to 88.88K	0	0	--	--	Show Txns Hide Txns

06-Mar-24 10:00 PM View:	30-Jan-24 Private Purchase $0.68K	Parker Geoffrey M. CHIEF FINANCIAL OFFICER		Allogene Therapeutics, Inc. - ALLO	100% 0 to 819.59K	0	0	--	--	Show Txns Hide Txns

31-Jan-24 5:48 PM View:	25-Jan-24 Grant 0	Douglas Earl Martin SVP, General Counsel		Allogene Therapeutics, Inc. - ALLO	100% 0 to 477.63K	0	0	--	--	Show Txns Hide Txns

Allogene Therapeutics, Inc. (ALLO)

Last Year

07-May-23 -- 06-May-24

Company Sentiment

Other

Other

Two Year Chart

07-May-22 -- 06-May-24

Price ($)

Sentiment

Buy & Sell Volume ($)

Recent Insider Trades

Buy:	0	--
Sell:	0	--